APCS

Across TCGA pan-cancer cohorts, APCS mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated APCS data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher APCS mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated APCS expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where APCS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.895	0.591	.005	23	view →
LUAD	OS	Median	II,III,IV	0.336	1.000	<.001	18	view →
UCEC	OS	Quartile	III,IV	0.258	1.000	.027	16	view →
GBM	DFS	Median	All	0.248	0.491	<.001	11	view →
HNSC	OS	Median	II,III,IV	0.616	0.818	.012	8	view →
LSCC	DFS	Quartile	II,III,IV	0.842	1.000	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

APCS–CCRCC (DFS)

Open the CCRCC breakdown →